[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631067":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":57,"centralContacts":63,"locations":69,"responsibleParty":87,"collaborators":57,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":57,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":57,"enrollmentInfo":98,"targetDuration":57,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":72,"whyStopped":57,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8,15,22,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort X Gen 2 Travoprost Intracameral Implant Arm","EXPERIMENTAL","Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 12 and be followed for an additional 12 months",[13,14],"Drug: Gen 2 Travoprost Intracameral Implant","Other: placebo eye drops",{"label":16,"type":17,"description":18,"interventionNames":19},"Cohort X Timolol Arm","ACTIVE_COMPARATOR","Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will administer timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo a sham exchange procedure at month 12 and be followed for an additional 12 months",[20,21],"Drug: Timolol eye drops 0.5%","Procedure: Sham Procedure",{"label":23,"type":17,"description":24,"interventionNames":25},"Cohort Y Gen 2 Travoprost Intracameral Implant Arm","Randomized, double-masked, active-controlled, Phase 3 portion of the trial, subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 24 and be followed for an additional 12 months",[13,14],{"label":27,"type":17,"description":28,"interventionNames":29},"Cohort Y Timolol Arm","Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will receive timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo a sham exchange procedure at month 24 and be followed for an additional 12 months",[20,21],{"label":31,"type":10,"description":32,"interventionNames":33},"Cohort Z Gen 2 Travoprost Intracameral Implant Arm","Randomized, double-masked, active-controlled, Phase 3 portion of the trial, subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and undergo an exchange procedure at month 36 and be followed for an additional 12 months",[13,14],{"label":35,"type":17,"description":36,"interventionNames":37},"Cohort Z Timolol Arm","Randomized, double-masked, active-controlled, Phase 3 portion of the trial; subjects will administer timolol 0.5% eye drops BID (plus sham procedure) in the study eye and undergo an sham exchange procedure at month 36 and be followed for an additional 12 months",[20,21],[39,46,52,58],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","Gen 2 Travoprost Intracameral Implant","Travoprost",[9,23,31],[45],"Gen 2 Travoprost Intraocular Implant",{"type":40,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"Timolol eye drops 0.5%","Timolol 0.5%",[16,27,35],[51],"Timolol maleate ophthalmic solution, 0.5%",{"type":53,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"PROCEDURE","Sham Procedure","Sham implant administration",[16,27,35],null,{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":57},"OTHER","placebo eye drops","Artificial Tears",[9,23,31],[64],{"name":65,"role":66,"phone":67,"phoneExt":57,"email":68},"Study Director","CONTACT","949-739-8749","ClinicalResearch@glaukos.com",[70],{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Glaukos Investigative Site","RECRUITING","Dothan","Alabama","36301","United States","US",{"type":79,"coordinates":80},"Point",[81,82],-85.39049,31.22323,{"lat":82,"lon":81},[85],{"name":86,"role":66,"phone":67,"phoneExt":57,"email":68},"Luis Vargas, MD",{"type":88,"investigatorFullName":57,"investigatorTitle":57,"investigatorAffiliation":57,"oldNameTitle":57,"oldOrganization":57},"SPONSOR","100631067","phase-3-trial-to-evaluate-the-safety-and-efficacy-of-the-second-generation-travoprost-intracameral-implant-100631067",false,"NCT07495852","Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","Inclusion Criteria:\n\n* Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye\n\nExclusion Criteria:\n\n* Prior incisional glaucoma surgery in the study eye\n* Prior argon laser trabeculoplasty (ALT) in the study eye\n* Prior minimally invasive glaucoma (MIGS) surgery in the study eye","ALL","18 Years",{"count":99,"type":100},510,"ESTIMATED","INTERVENTIONAL",[103],"PHASE3","Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant",[106],"Glaucoma",[108,109],"Open Angle Glaucoma","Ocular hypertension","2026-03-25",{"date":112,"type":113},"2026-03-30","ACTUAL",{"date":115,"type":113},"2026-02-17",{"date":117,"type":100},"2032-03",{"name":5,"class":6},1]